"The second quarter of the year saw an improvement in EBIT compared with recent quarters, continued high gross margins, strong growth and an exclusive collaboration and distribution agreement with US-based
Fredrik Alpsten, CEO, Devyser
The quarter from April to
- Net sales amounted to
SEK 37.7 million (30.9), corresponding to a 22.3% increase. Adjusted for exchange rate fluctuations, net sales increased by 12.6%. -
Gross profit totaled
SEK 31.5 million (24.7), corresponding to a gross margin of 83.4% (79.9). -
Operating profit (EBIT) amounted to
SEK -13.5 million (-12.6). -
Profit after tax totaled
SEK -14.6 million (-14.3). -
Earnings per share before and after dilution amounted to
SEK -0.90 (-0.90). -
Cash flow from operating activities stood at
SEK -22.8 million (-7.9).
The period from January to
- Net sales amounted to
SEK 77.2 million (61.3), corresponding to a 26.1% increase. Adjusted for exchange rate fluctuations, net sales increased by 17.3%. -
Gross profit totaled
SEK 65.1 million (49.9), corresponding to a gross margin of 84.3% (81.4). -
Operating profit (EBIT) amounted to
SEK -32.6 million (-17.9). -
Profit after tax totaled
SEK -34.5 million (-20.4). -
Earnings per share before and after dilution amounted to
SEK -2.14 (-1.29). -
Cash flow from operating activities stood at
SEK -42.1 million (-15.3).
Important events during the quarter
Devyser launches first IVDR-certified product
In March, Devyser launched Compact, the company's first IVDR-certified product. This is a rapid genetic test for the diagnosis of fetal chromosomal abnormalities, and is the first in its field to be approved in accordance with the IVDR, the new, more comprehensive, European regulatory framework that came into force in
Agreement with
Devyser signed an exclusive collaboration and distribution agreement with
Winner of the Swecare Export Award 2023
Devyser received the Swecare Export Award 2023 in April. This prize is awarded to companies that "with creativity, commitment and scope put Swedish innovation in health and healthcare on the world map". The award was presented by Minister for Social Affairs Jacob Forssmed.
CLIA certification of Devyser's clinical laboratory
Devyser's clinical testing laboratory in
Annual General Meeting
At the Annual General Meeting in May, Mia Arnhult, Lars Höckenström,
Approval of Devyser's RHD product in
In June, Devyser was granted regulatory approval in
Devyser's Deputy CEO and founder Ulf Klangby moves to an advisory role
In June, Devyser announced that Ulf Klangby would leave his position on
Launching of two new genetic tests for hereditary cancers
At the end of June, Devyser launched two new products, Devyser LynchFAP and Devyser BRCA PALB2. The products offer efficient, targeted and safe analysis of genes associated with an increased cancer risk, such as the genes implicated in Lynch syndrome and in breast and ovarian cancer.
Important events after the end of the quarter
IVDR approval of Devyser's transplant products
Devyser's new test for the detection of donor-derived cell-free DNA in blood samples from kidney transplant patients, and the company's product for the screening and follow-up of stem cell transplant patients, were given IVDR approval in July.
Presentation
The report will be presented at an audiocast at
This report and previous financial reports are available on the company's webpage https://investors.devyser.com/en/reports-presentations.
This information is information that
For more information, please contact:
Fredrik Alpsten, CEO
E-mail: fredrik.alpsten@devyser.com
Tel: +46 706 673 106
E-mail: sabina.berlin@devyser.com
Tel: +46 739 519 502
About
Devyser develops, manufactures and sells diagnostic solutions and analysis services to clinical laboratories in more than 50 countries. Our products are used for complex genetic testing in the hereditary disease, oncology and transplant fields, to enable targeted cancer treatment, the diagnosis of a large number of genetic diseases, and transplant patient follow-up. Devyser's products, and unique, patented solution requiring only one test tube, simplify genetic testing processes, improve sample throughput, minimize hands-on time and deliver rapid results. Our goal is for every patient to receive a correct diagnosis in the shortest possible time.
Devyser was founded in 2004 and is based in
Devyser's shares are listed on the Nasdaq First North Premier Growth Market Stockholm (ticker: DVYSR). The company's Certified Adviser is
For more information, visit www.devyser.com
https://news.cision.com/devyser-diagnostics-ab/r/devyser-diagnostics-ab-publishes-quarterly-report-for-the-period-april-to-june-2023,c3821799
https://mb.cision.com/Main/13649/3821799/2242864.pdf
(c) 2023 Cision. All rights reserved., source